ES2179729B1 - Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. - Google Patents
Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.Info
- Publication number
- ES2179729B1 ES2179729B1 ES200000710A ES200000710A ES2179729B1 ES 2179729 B1 ES2179729 B1 ES 2179729B1 ES 200000710 A ES200000710 A ES 200000710A ES 200000710 A ES200000710 A ES 200000710A ES 2179729 B1 ES2179729 B1 ES 2179729B1
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical form
- obtaining
- water
- presentation
- isoniazid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003350 isoniazid Drugs 0.000 title abstract 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 title abstract 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 title abstract 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 title 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 abstract 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 abstract 3
- 229960001225 rifampicin Drugs 0.000 abstract 3
- 239000008187 granular material Substances 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940049413 rifampicin and isoniazid Drugs 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Forma farmacéutica sólida de administración oral dispersable en agua que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtención y forma de presentación de dicha forma farmacéutica. La forma farmacéutica contiene rifampicina, isoniazida y piridoxina hidrocloruro como principios activos, en una matriz sólida granular dispersable en agua, que puede ser reconstituida en agua, dando lugar a una suspensión de sabor agradable. El procedimiento de obtención de dicha forma farmacéutica comprende la mezcla simple de los componentes o bien la obtención, por separado, de unos granulados de rifampicina y de isoniazida, y la mezcla y homogeneización de dichos granulados. La forma farmacéutica es adecuada para la elaboración de una forma de presentación de un medicamento que contiene rifampicina, isoniazida y piridoxina hidrocloruro, por ejemplo, en forma de sobres monodosis que contienen dicha forma farmacéutica en una dosificación terapéuticamente.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000710A ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
| PCT/ES2001/000089 WO2001070172A2 (es) | 2000-03-23 | 2001-03-08 | Forma farmaceutica solida de administracion oral dispersable en agua que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000710A ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2179729A1 ES2179729A1 (es) | 2003-01-16 |
| ES2179729B1 true ES2179729B1 (es) | 2003-12-16 |
Family
ID=8492832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200000710A Expired - Fee Related ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2179729B1 (es) |
| WO (1) | WO2001070172A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20021319A3 (cs) * | 2000-08-09 | 2002-08-14 | Panacea Biotec Limited | Farmaceutické prostředky anti-tuberkulárního léčiva a způsob jejich přípravy |
| WO2004082586A2 (en) * | 2003-03-17 | 2004-09-30 | Affinium Pharmaceuticals, Inc. | Phamaceutical compositions comprising inhibitors of fab i and further antibiotics |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| WO2008098374A1 (en) | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
| KR101720885B1 (ko) | 2012-06-19 | 2017-03-28 | 데비오팜 인터네셔날 에스 에이 | (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체 |
| CN103816545A (zh) * | 2013-10-30 | 2014-05-28 | 安徽万邦医药科技有限公司 | 含有利福平和十二烷基硫酸钠的药物组合物 |
| RS61312B1 (sr) | 2016-02-26 | 2021-02-26 | Debiopharm Int Sa | Lek za lečenje infekcija dijabetskog stopala |
| MY203711A (en) | 2019-02-14 | 2024-07-15 | Debiopharm Int Sa | Afabicin formulation, method for making the same and uses thereof |
| JP7418475B2 (ja) | 2019-06-14 | 2024-01-19 | デバイオファーム インターナショナル エス．エー． | バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1755780A1 (ru) * | 1989-10-30 | 1992-08-23 | Киевский государственный институт усовершенствования врачей | "Сухой безалкогольный напиток "Стимул" |
| BR9711148A (pt) * | 1996-08-14 | 1999-08-17 | Zamonouchi Europ Bv | Granulados compreendendo composto solÚvel em gua e celulose |
| IT1289883B1 (it) * | 1996-10-09 | 1998-10-19 | Lupin Lab Ltd | Composizione farmaceutica antitubercolare e procedimento per la sua produzione |
-
2000
- 2000-03-23 ES ES200000710A patent/ES2179729B1/es not_active Expired - Fee Related
-
2001
- 2001-03-08 WO PCT/ES2001/000089 patent/WO2001070172A2/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001070172A3 (es) | 2002-01-31 |
| WO2001070172A2 (es) | 2001-09-27 |
| ES2179729A1 (es) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
| ECSP045102A (es) | Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo | |
| BRPI0403935B8 (pt) | formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| NO20025621D0 (no) | Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser | |
| TW200505498A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
| PT833618E (pt) | Forma farmaceutica solida para utilizacao oral | |
| SE0102276D0 (sv) | Device and method for the administration of a medicament | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| ECSP045409A (es) | Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
| EP1365749A4 (en) | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| ES2179729B1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| NO20031409L (no) | Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| ES2184561B1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo rifampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| CA2386547C (en) | Orally disintegrating composition comprising mirtazapine | |
| WO2003061557A3 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| WO2003045305A3 (en) | Acetaminophen compositions | |
| DK1530459T3 (da) | Oral farmaceutisk sammensætning til bløde kapsler indeholdende vinorelbin samt fremgangsmåde til behandling | |
| AP2218A (en) | Azithromycin dosage forms with reduced side effects | |
| WO2002056867A3 (en) | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20030116 Kind code of ref document: A1 |
|
| PC2A | Transfer of patent | ||
| FG2A | Definitive protection |
Ref document number: 2179729B1 Country of ref document: ES |
|
| PC2A | Transfer of patent |
Free format text: CHIESI ESPANA, S.A. |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20200630 |